Home › Trials › NCT07306338
Clinical trial Recruiting at 1 site Observational Ages 18 and up

Interest in integrative oncology services at USC Norris Cancer Center

Official title: Patient Interest in an Integrative Oncology Program at USC Norris Cancer Center: A Single-Institution Needs Assessment

Run by University of Southern California · NCT07306338 · Data updated 2026-11-12

This project will see if adult patients with solid tumors or blood cancers at USC Norris and Keck HC3 are interested in and able to use integrative oncology services and what barriers might limit participation.

More Malignant Solid Neoplasm trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment10 (estimated)
SponsorUniversity of Southern California
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedDecember 15, 2025
Main results expectedJanuary 31, 2027
Study endsJanuary 31, 2028
Registry record updatedMarch 27, 2026
Trial IDNCT07306338 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with a diagnosed solid tumor or hematologic malignancy who receive care at USC Norris outpatient clinics or the Keck HC3 Women's Health clinic and who speak English, Spanish, or Chinese.

Probably not a fit

People who cannot give informed consent or who are not patients at the participating USC clinics (or do not speak the supported languages) are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational needs-assessment uses patient surveys and optional focus groups to measure knowledge, attitudes, interest, and potential barriers to an integrative oncology program at USC Norris and the Keck HC3 Women's Clinic. Participants are adult oncology outpatients who speak English, Spanish, or Chinese and have a diagnosed solid or hematologic malignancy. The study will identify predictors of willingness to participate or refer and explore feasibility of integrating services into clinic workflows. Findings will inform how and whether integrative services could be implemented locally.

Why it matters

Potential benefit: If successful, the results could support adding tailored integrative therapies to routine cancer care to improve symptom management and patient experience.

How similar studies have gone: Other integrative oncology programs and studies have shown benefits for symptom control and patient satisfaction, though implementation approaches vary and needs-assessment work like this is commonly used before program rollout.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18 years
* Ability to understand and the willingness to participate in the study.
* English, Spanish, or Chinese speaking
* Patient of USC NCCC Outpatient Clinics or Keck HC3 Women's Health outpatient clinic.
* Diagnosed solid or hematologic Malignancy

Exclusion Criteria:

* Unable to provide informed consent

Where it's running

  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California, United States     Recruiting

Study contacts

  • Principal investigator: Xiaoyue M Guo — University of Southern California

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hematopoietic and Lymphatic System Neoplasm 55Malignant Solid Neoplasm 97University of Southern California 1140
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.